Atlas Trials

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Clinical trial NCT04825860 · TERMINATED

Trial details

NCT number
NCT04825860
Sponsor
Sumitomo Pharma Co., Ltd.
Status
TERMINATED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Schizophrenia
Start date
2021-03-29
Primary completion
2023-10-12
Enrollment
83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.